Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Why Catalent Stock Soared Today
06:25pm, Monday, 05'th Feb 2024
The pharmaceuticals manufacturing leader is being acquired by Novo Holdings. The transaction should close toward the end of 2024.
Novo Holdings Buyout Sends Catalent Stock Surging
11:07am, Monday, 05'th Feb 2024
The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5
Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
11:05am, Monday, 05'th Feb 2024
Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
10:57am, Monday, 05'th Feb 2024
Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Ho
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
09:19am, Monday, 05'th Feb 2024
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.
Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder
07:46am, Monday, 05'th Feb 2024
Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)'s controlling shareholder was to buy the firm for US$16.5 billion.
Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk
06:38am, Monday, 05'th Feb 2024
Novo Holdings will acquire Catalent for $63.50 a share in cash.
Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity
06:19am, Monday, 05'th Feb 2024
Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss
Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion
06:15am, Monday, 05'th Feb 2024
Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's clos
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo
05:04am, Wednesday, 31'st Jan 2024
Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost
Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast
01:35pm, Friday, 26'th Jan 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ
Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:44am, Thursday, 04'th Jan 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executi
Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?
12:46pm, Friday, 15'th Dec 2023
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Catalent (CTLT) Stock for Now
12:01pm, Friday, 15'th Dec 2023
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales
10:34am, Thursday, 16'th Nov 2023
Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.
